| Dr Janel Lacey Nielsen, DO | |
|
15 Hospital Dr, York, ME 03909-1011 | |
| (801) 450-4790 | |
| Not Available |
| Full Name | Dr Janel Lacey Nielsen |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 15 Hospital Dr, York, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477743771 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | OTO11501 (Pennsylvania) | Secondary |
| 207L00000X | Anesthesiology | 4063 (Iowa) | Secondary |
| 207L00000X | Anesthesiology | 2253 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| York Hospital | 6406766781 | 169 |
News Archive
Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 2 days ago
| Entity Name | York Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376528398 PECOS PAC ID: 6406766781 Enrollment ID: O20040812001065 |
News Archive
Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Janel Lacey Nielsen, DO 15 Hospital Dr, York, ME 03909-1011 Ph: (801) 450-4790 | Dr Janel Lacey Nielsen, DO 15 Hospital Dr, York, ME 03909-1011 Ph: (801) 450-4790 |
News Archive
Zoetis Inc. today reported its financial results for the first quarter of 2014. The company reported revenue of $1.1 billion for the first quarter of 2014, an increase of 1% from the first quarter of 2013. Revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 2 days ago
Dr. Timothy J Hall, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 207-351-2400 Fax: 207-351-2193 | |
Dr. Jeffrey Michael Lockhart, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 207-351-2407 Fax: 207-351-2193 | |
Arthur Jules Gamache Jr., MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 207-351-2244 | |
Jamin Chi, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 207-351-2244 | |
Dr. Lauren N/a Mckinley, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 15 Hospital Dr, York, ME 03909 Phone: 970-988-7264 |